Founding teams
A crystal clear commercial vision helps investors immediately grasp the proposition.
A crystal clear commercial vision helps investors immediately grasp the proposition. It also provides clarity on the route to the next value inflection point.
Auxinia works with founding teams to synthesise an evidence-based, assumption-tested, compelling story to showcase the problem you are working on, why it matters and your strategy to solve it.
Building a biotech takes courage, perseverance and great science.
To give your science the best chance of success, you need to be able to bring investors and partners along the journey with you. A key part of this is the ability to communicate a concise, compelling and credible commercial story.
Take the diagnostic below to uncover blind spots
Diagnostic
What is your idea?
Can you describe the journey to your destination?
What do you need to get there?
Is it worth the effort?
What is your next value inflection point?
Which way will you turn next?
Can Auxinia help?
The approach
Deep dive first
Flexible and bespoke
Responsibly supported by AI
Contact
Book a scoping call
Send a message
Founding teams
A crystal clear commercial vision helps investors immediately grasp the proposition.
Book a scoping callTake the diagnosticA crystal clear commercial vision helps investors immediately grasp the proposition. It also provides clarity on the route to the next value inflection point.
Auxinia works with founding teams to synthesise an evidence-based, assumption-tested, compelling story to showcase the problem you are working on, why it matters and your strategy to solve it.
Building a biotech takes courage, perseverance and great science.
To give your science the best chance of success, you need to be able to bring investors and partners along the journey with you. A key part of this is the ability to communicate a concise, compelling and credible commercial story.
Take the diagnostic below to uncover blind spots
Diagnostic
- What are you developing, and who does it help?
- What is it worth to them?
- Who actually pays?
- How and why would they pay?
- Who else is solving this problem, and how are you different?
- What is your vision of success?
- What are the key derisking events between here and there?
- What value does each one unlock?
- Will you go all the way or when/how do you plan to exit?
- Who are the likely buyers or partners at this point?
- What will they need to see?
- What do you need to do for each derisking event?
- How long will each stage take?
- What will each stage cost?
- When will you need capital and how much will you need?
- When will capital be cheapest without risking overvaluation and a down-round?
- How and when will investors see returns?
- How much capital does the whole journey require?
- Does the potential value justify the total investment and risk?
- How will you still be ahead of the competition by the time you reach market?
- What upcoming derisking event most changes the value of your asset?
- What does success unlock?
- If it fails, what happens to the plan?
- Are your time, team and budget aligned behind it?
- What strategic choices are ahead of you?
- What would help you make a decision?
The approach
Deep dive firstLong-term engagements start with in-depth foundational research. That is what makes the intelligence that follows specific to the nuances of your situation.
Flexible and bespokeCash-flow uncertainty is a common part of the biotech journey. Unlike a salary, retainers can be paused to cover periods of low funding. Ad-hoc projects bring in the expertise as and when you need it.
Responsibly supported by AIMany aspects of commercial intelligence can be enhanced by the thoughtful application of AI. Auxinia treats AI as a highly competent but untrustworthy intern bringing the benefit of experienced human oversight with machine efficiency.
Auxinia works on an anti-slop basis. Every claim is rigorously validated and sense-checked for accuracy and relevance.